Highlights

  • MAIA agreed to issue over 1.23 million common shares in a private placement transaction.
  • The offering includes warrants exercisable at USD 1.36 per share after six months.
  • Net proceeds are earmarked for Phase II THIO-101 trial activities and working capital needs.

MAIA Biotechnology, Inc. (NYSE:MAIA)a clinical-stage biopharmaceutical company, announced that it has entered into definitive agreements for a private placement involving the issuance of 1,233,488 shares of common stock. The shares are being sold at a purchase price of USD 1.224 per share to accredited investors and a participating company director. Each share is accompanied by a warrant to purchase one additional share of common stock.

The warrants carry an exercise price of USD 1.36 per share, which aligns with the minimum price requirements under NYSE American Rule 713, subject to customary adjustments. These warrants will become exercisable six months after issuance and will remain outstanding for a term of three years from the issuance date.

Expected Proceeds and Closing Timeline
The gross proceeds from the private placement are expected to total approximately USD 1.51 million, before deducting offering-related expenses payable by the company. The transaction is anticipated to close on or around December 18, 2025, subject to the satisfaction of customary closing conditions.

Shares issued to the company director participating in the offering are being granted under MAIA’s 2021 Equity Incentive Plan. The remaining securities are being issued to accredited investors under applicable private placement exemptions.

Use of Funds Allocation
According to the company, the net proceeds from the offering are intended to be used to fund the execution of Step 1 of Part C of the Phase II THIO-101 clinical trial. Additional funds are expected to support general working capital requirements. The THIO-101 study relates to the clinical development of ateganosine (THIO), MAIA’s lead investigational program.

Regulatory and Securities Law Considerations
The securities offered in this transaction are being issued under Section 4(a)(2) of the Securities Act of 1933 and Regulation D. The shares, warrants, and underlying common stock have not been registered under the Securities Act or applicable state securities laws. As a result, they may not be offered or sold in the United States unless registered or exempt from registration requirements.

The company also clarified that the announcement does not constitute an offer to sell or a solicitation to buy any securities in any jurisdiction where such actions would be unlawful prior to appropriate registration or qualification under relevant securities laws.

Share Price Snapshot
MAIA shares closed at USD 1.23 on 16 December, down 8.89%. The stock traded between an intraday high of USD 1.35 and a low of USD 1.22 after opening at USD 1.32.